Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Search trials by disease or condition

Enter a condition, keyword, or NCT ID

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “lung cancer”

Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.Active Not Recruiting
NCT05445843Phase 2Updated Sep 10, 2026
Sponsor: Novartis Pharmaceuticals
Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
United States, Argentina, Austria, Belgium, Brazil +14 more
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory DiseaseNot Yet Recruiting
NCT07509034Phase 1Updated Sep 10, 2026
Sponsor: National Cancer Institute (NCI)
Extensive-Stage Small Cell Lung Cancer · Extrapulmonary Neuroendocrine Carcinoma · Recurrent or Refractory · Solid Tumors
United States
Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung CancerSuspended
NCT05642195Phase 1, Phase 2Updated Sep 10, 2026
Sponsor: National Cancer Institute (NCI)
Non-Small Cell Lung Cancer · Non-Small Cell Lung Carcinoma · Carcinoma, Non-Small-Cell Lung · Carcinomas
United States
Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLCActive Not Recruiting
NCT02259621Phase 2Updated Sep 10, 2026
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Non-Small Cell Lung Cancer
United States, Canada
A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid TumorsNot Yet Recruiting
NCT07814248Phase 1Updated Sep 10, 2026
Sponsor: TwoStep Therapeutics, Inc.
NSCLC (Non-small Cell Lung Cancer) · HNSCC · Endometrial · Ovarian Cancer
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)Recruiting
NCT04302025Phase 2Updated Sep 10, 2026
Sponsor: Genentech, Inc.
Non-small Cell Lung Cancer
United States
Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLCActive Not Recruiting
NCT04958811Phase 2Updated Sep 10, 2026
Sponsor: Georgetown University
Non-squamous Non-small-cell Lung Cancer
United States
A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid TumorsRecruiting
NCT07730021Phase 1, Phase 2Updated Sep 10, 2026
Sponsor: Astellas Pharma Global Development, Inc.
Locally Advanced or Metastatic Solid Tumors
United States
Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)Suspended
NCT06694454Phase 1, Phase 2Updated Sep 10, 2026
Sponsor: National Cancer Institute (NCI)
Non-small Cell Lung Cancer (NSCLC) · Carcinoma, Non-Small Cell Lung · Non-Small Cell Lung Carcinoma · Non Small Cell Lung Cancer
United States
Virus-associated Tumour MicroenvironmentRecruiting
NCT06471296N/AUpdated Sep 10, 2026
Sponsor: Assistance Publique - Hôpitaux de Paris
Lymphoma · Cancers of the Lung · Cancer Anal Canal
France
Non-ablative Oligofractionated Radiation Therapy Before Surgical Transplantation As RadiovaccinationRecruiting
NCT04782752NAUpdated Sep 10, 2026
Sponsor: Marc de Perrot
Transplant-Related Lung Cancer
Canada
Real-Time Non-Invasive Localization for Multiple Lung NodulesCompleted
NCT07257549NAUpdated Sep 10, 2026
Sponsor: The First Affiliated Hospital of Guangzhou Medical University
Lung Cancer (NSCLC)
China
EIT Evaluation of Pulmonary Ventilation With Different Ropivacaine Concentrations in Intercostal Nerve BlockadeCompleted
NCT07079436NAUpdated Sep 10, 2026
Sponsor: Fudan University
Intercostal Nerve Block · Pulmonary Ventilation · Anesthesia, Local · Breast Neoplasms
China
Clinical Genetics Branch Eligibility Screening SurveyNot Yet Recruiting
NCT07005297N/AUpdated Sep 10, 2026
Sponsor: National Cancer Institute (NCI)
Melanoma · Li-Fraumeni Syndrome · Pulmonary Blastoma · Chordoma
United States
Comparison of Perioperative Immunotherapy, Adjuvant Immunotherapy or Neoadjuvant Immunotherapy for Resectable Stage II-IIIA NSCLCRecruiting
NCT07554846Phase 3Updated Sep 10, 2026
Sponsor: Fudan University
Resectable Stage II-IIIa NSCLC
China
Usefulness of Thromboelastography as a Predictor of Prognosis in Patients Undergoing Surgery for Glial Tumors and of the Risk of Postoperative Thromboembolic Disease (GliTEM)Recruiting
NCT07813377N/AUpdated Sep 10, 2026
Sponsor: Fundacion Clinic per a la Recerca Biomédica
Glial Tumors · Thrombosis · Pulmonary Embolism (Diagnosis)
Spain
Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma (POELH-III)Recruiting
NCT07161869N/AUpdated Sep 10, 2026
Sponsor: Erasmus Medical Center
Hilar Cholangiocarcinoma · Intrahepatic Cholangiocarcinoma (Icc) · Cholangiocarcinoma · Perihilar Cholangiocarcinoma
Netherlands
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)Active Not Recruiting
NCT04624204Phase 3Updated Sep 10, 2026
Sponsor: Merck Sharp & Dohme LLC
Small Cell Lung Cancer
United States, Australia, Belgium, Bulgaria, Canada +20 more
Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib TreatmentRecruiting
NCT06106802Phase 2Updated Sep 10, 2026
Sponsor: Sehhoon Park
Non-Small Cell Lung Cancer Metastatic
South Korea
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLCRecruiting
NCT06303505Phase 1, Phase 2Updated Sep 9, 2026
Sponsor: Tubulis GmbH
Ovarian Cancer · Non-small Cell Lung Cancer
United States, Belgium, Germany, Romania, Spain +2 more
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study TreatmentsRecruiting
NCT07468071Phase 1, Phase 2Updated Sep 9, 2026
Sponsor: Novartis Pharmaceuticals
Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer · Advanced Solid Tumors Harboring the KRAS G12C Mutation
Belgium, Canada, China, Denmark, France +5 more
A Study of [68Ga]Ga-DWJ155 in Adult Patients With Solid TumorsRecruiting
NCT07801508Phase 1Updated Sep 9, 2026
Sponsor: Novartis Pharmaceuticals
Advanced Gastroesophageal Adenocarcinoma · Advanced Breast Cancer · Triple-negative Breast Cancer · Advanced Non-small Cell Lung Cancer
Japan
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain MetastasesRecruiting
NCT04899908Phase 2Updated Sep 9, 2026
Sponsor: Brigham and Women's Hospital
Brain Cancer · Brain Metastases · Melanoma · Lung Cancer
United States
A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based ChemotherapyActive Not Recruiting
NCT05941897Phase 2Updated Sep 9, 2026
Sponsor: AstraZeneca
Advanced or Metastatic NSCLC
Russia
Osimertinib With or Without Primary Lung Tumor Resection for EGFR-Mutant Oligometastatic Non-Small Cell Lung CancerRecruiting
NCT07738172Phase 3Updated Sep 9, 2026
Sponsor: National Taiwan University Hospital
Lung Neoplasms, Non-Small Cell Lung Cancer
Taiwan

Previous page Next page